Investing Aclaris Therapeutics: New Data From Phase 3 Of Development SoonSeeking Alpha - GG Pharma Research With one product candidate at Phase 3 of development and expecting completion in early 2020, Aclaris Therapeutics (ACRS) is a name to be followed …
Investing Avoid The Intrexon HypeSeeking Alpha - Alpha Generator Intrexon Corporation (XON) has been on an interesting ride this year, starting the year in the $7/share range before dropping massively to …
Investing Dicerna And DCR-A1AT In Alpha-1 Antitrypsin Deficiency-Associated Liver DiseaseSeeking Alpha - First Genesis Consulting Dicerna Pharmaceuticals (DRNA) is a small-cap ($980M) developing RNA interference (RNAi) based therapeutics for rare and/or chronic diseases …
Nektar Therapeutics Nektar Hammered On Multiple Setbacks; Core Efficacy Questions Remain OpenSeeking Alpha - Stephen Simpson, CFA The last three months have been rough for Nektar Therapeutics (NKTR) and its shareholders, as the company announced significant manufacturing issues …
Investing Exagen: Promising Growth StorySeeking Alpha - The Value Investor Exagen (NASDAQ:XGN) has gone public in an offering which was initially not well received by the market, yet the scepticism has disappeared quickly. …
Investing Blast Off With Rocket PharmaceuticalsSeeking Alpha - The Twilight Investor Editor's note: Seeking Alpha is proud to welcome The Twilight Investor as a new contributor. It's easy to become a Seeking Alpha contributor and earn …
Quote Symbol …Peak Bggr https://www-newscientist-com.cdn.ampproject.org/c/s/www.newscientist.com/article/2217255-herpes-vaccine-to-be-tested-in-humans-after-best-result-yet-in-animals/amp/
Immunotherapy CAR T cell therapy: On the cusp of 'an immunotherapy revolution'?ampproject.org - Delthia Ricks A deeper understanding of the immune system's role in controlling cancer has helped drive "an immunotherapy revolution," offering hope for many …
Icon version of the Flipboard logo World’s first gene therapy for glycogen storage disease produces remarkable resultsbioengineer.org - Bioengineer At the Association for Glycogen Storage Disease’s 41st Annual Conference, Dr. David Weinstein of UConn School of Medicine and Connecticut Children’s …
Investing Go-Private Offer For China Biologic Products: It Is UndervaluedSeeking Alpha - AAC Financial Research China Biologic Products (CBPO) received a $120 per share offer to take the company private. The newly elected CEO has a lot of expertise in the M&A …
Alzheimer's Disease Alzheimer's: Head device reduces memory loss in 7 out of 8 peopleMedical News Today - By Maria Cohut, Ph.D. An open-label clinical trial working with eight people with Alzheimer's disease concluded that a new wearable device that emits electromagnetic …
Investing T2 Biosystems RebornSeeking Alpha - George Kesarios On my previous article on T2 Biosystems (TTOO), I said my next article would be about putting some numbers together and coming up with a possible …
Japan Takeda's antidepressant Trintellix OK'd in JapanSeeking Alpha - Douglas W. House Japan's Ministry of Health, Labor and Welfare has approved Takeda's (TAK +1.1%) Trintellix (vortioxetine) for the treatment of major depressive …
Novo Nordisk FDA OKs Novo oral pill for T2D; shares up 3%Seeking Alpha - Douglas W. House The FDA approves Novo Nordisk's (NVO +2.6%) oral tablet Rybelsus (semaglutide) to improve blood sugar control in adults with type 2 diabetes …
Investing 6 September Healthcare IPOs Investors Should Take Stock OfThe Motley Fool - David Haen The recent crop of new stocks runs the gamut from R&D stage biotech to a Fortune 500 spin-off with billions in revenue. School is back in session, …
Teva Drug makers up after McConnell thumbs down on Pelosi price pricing planSeeking Alpha - Douglas W. House Members of Big Biopharma are in the green as investors exhale after Senate Majority Leader Mitch McConnell (R-KY) warned House Speaker Nancy Pelosi …
Nasdaq Healthcare - Top 5 Gainers / LosersSeeking Alpha - Akanksha Bakshi Gainers: Midatech Pharma (NASDAQ:MTP) +29%. Gamida Cell (NASDAQ:GMDA) +19%. AMAG Pharmaceuticals (NASDAQ:AMAG) +11%. Akorn (NASDAQ:AKRX) +10%. …
Investing ImmunoGen: A Long-Term Investment Based On Its ADC TechnologySeeking Alpha - Avisol Capital Partners ImmunoGen, Inc. (IMGN) failed a phase 3 trial called FORWARD 1 involving lead drug candidate mirvetuximab in platinum-resistant ovarian cancer, but …
Investing Regenxbio And RGX-501 In Homozygous Familial HypercholesterolemiaSeeking Alpha - First Genesis Consulting In Q2/2019, Regenxbio Inc. (RGNX), achieved its first commercial-stage success with FDA approval of Zolgensma, a gene therapy infusion therapy for …
Ophthalmology European advisory group backs Aerie's RhokiinsaSeeking Alpha - Douglas W. House The European Medicines Agency's advisory group CHMP adopts a positive opinion backing approval of Aerie Pharmaceuticals' (NASDAQ:AERI) Rhokiinsa …
Japan Astellas Pharma and FibroGen's roxadustat OK'd in JapanSeeking Alpha - Douglas W. House FibroGen (NASDAQ:FGEN) and collaboration partner Astellas Pharma (OTCPK:ALPMF) announce approval of Evrenzo (roxadustat) in Japan for the treatment …
FDA FDA OKs Roche whole blood Babesia test for donor screeningSeeking Alpha - Douglas W. House The FDA approves Roche's (OTCQX:RHHBY) cobas Babesia test for use on the automated cobas 6800/8800 systems for individual blood donation testing. The …
Metformin European advisory group backs AstraZeneca combo pill for T2DSeeking Alpha - Douglas W. House The European Medicine Agency's advisory group CHMP has adopted a positive opinion recommending approval of AstraZeneca's (NYSE:AZN) Qtrilmet (850 mg …
Leukemia European advisory group backs Astellas Pharma's gilteritinib for certain type of leukemiaSeeking Alpha - Douglas W. House The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Astellas Pharma Europe B.V.'s …
Lupus European advisory group backs label expansion of Glaxo's BenlystaSeeking Alpha - Douglas W. House The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending the use of GlaxoSmithKline's (NYSE:GSK) Benlysta …
Sinusitis European advisory group backs expanded use of DupixentSeeking Alpha - Douglas W. House The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Regeneron Pharmaceuticals (NASDAQ:REGN) …
Novartis European advisory groups backs expanded use of LucentisSeeking Alpha - Douglas W. House The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Novartis Europharm Limited's (NYSE:NVS) …
Investing Johnson & Johnson: Opportunity Beckons - Know When To StrikeSeeking Alpha - Robert Honeywill The Opioid Threat Is Highly Manageable From A Financial Perspective Johnson & Johnson (NYSE:JNJ) is currently trading at an adjusted non-GAAP P/E …
Eli Lilly AC Immune earns CHF30M milestone from Eli LillySeeking Alpha - Mamta Mayani AC Immune SA (NASDAQ:ACIU) will receive the first milestone payment of CHF30M from Eli Lilly (NYSE:LLY) on or before October 7, 2019. This payment is …
